Top Injectable Manufacturer in Timor-Leste – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 5 hours ago
- 7 min read
Last Updated: September 6, 2026
TL;DR: Timor-Leste answers the question we ask of every market — does it name the regulators it will lean on, and is India's CDSCO among them — with a named list on which CDSCO does not appear. The list is a route switch, not a bar: question E1 of the DNFM's registration form names ten agencies plus WHO prequalification, yes sends the file to Route A and no sends it to Route B, and both branches end in a registration number. Two harder facts frame it: the statutory basis is in transition, and the applicant must be an importer seated in the country.
Key Takeaways
A named list, and CDSCO is not on it — but WHO prequalification is. Question E1 of the DNFM importer application form of January 2024 names Indonesia's BPOM, Singapore's HSA, Thailand's FDA, Malaysia's NPRA, the TGA, the EMA, Health Canada, Swissmedic, Japan's PMDA and the US FDA, plus WHO prequalification. CDSCO is absent there, and from the 2018 form and 2023 checklist. WHO's August 2026 list records CDSCO at maturity level 3 with the scope 'Vaccines (producing)' only.
Route B is a documentation route, not a refusal: a GMP certificate for the finished-product site issued no longer than two years ago, a valid CPP for export to Timor-Leste — free-sale certificates are not accepted in its place — a batch certificate of analysis, the list of countries where the product is approved, three-batch stability with the climate zone declared, a full ASEAN Common Technical Dossier on USB, and a sample. The DAIM procedure sets a 30-day target and 90-day maximum.
The legal basis is in transition and should be said plainly. Decree-Law 12/2004 was repealed in full by Article 77 of Decree-Law 2/2025, in force from 23 January 2025, although the DNFM's forms still cite it. Article 56(2) cross-refers to a marketing-authorisation decree-law that we searched for in the Jornal da República for 2025 and 2026 and did not find published.
You cannot be the applicant, and the money is at INFPM. Article 44(a) of Decree-Law 2/2025 requires the authorisation-holder to be seated in national territory and Article 44(d) requires a pharmacist as technical director. SAMES was succeeded by the Instituto Nacional de Farmácia e Produtos Médicos under Decree-Law 57/2023, which publishes tenders and awards; our own approximate count of its published medicine awards is twelve lines worth about USD 2.01 million.
Introduction: Why Timor-Leste Demands a Premium Injectable Manufacturer in Timor-Leste
Every market in this series opens with the same question: does the country publish a list of regulatory authorities whose decisions it will lean on, and is India's CDSCO among them? Timor-Leste answers it in one line on a form. Question E1 of the DNFM importer medicine application form, version 2.1 of January 2024, asks whether the product is approved by one of ten named agencies — among them Indonesia's BPOM, Singapore's HSA, the TGA, the EMA and the US FDA — or is WHO-prequalified. Yes sends the file to Route A; no sends it to Route B. CDSCO is not among them, and it is absent from the 2018 form and the September 2023 checklist too.
That absence is not exclusion. Nothing we read says a product from an unlisted country is refused, and the registration numbering scheme — AIMTL, year, route letter, sequence — shows Route B files end in registrations. A published DNFM FAQ states the intent plainly: future requirements will streamline registration for medicines authorised by trusted regulatory bodies, while additional data is needed for others. So the answer costs paperwork rather than access, and a serious injectable manufacturer in Timor-Leste plans for it. One caution: the 2018 form, the 2023 checklist and the 2024 forms remain published simultaneously with overlapping but not identical country sets, and we could not establish which is currently operative.
What Sets a World-Class Injectable Manufacturer in Timor-Leste Apart
The rules about your factory and the rules about your buyer's licence are different rules, and here the binding one sits on the buyer. On the factory side the requirements are demanding but not origin-restricted: the GMP certificate must be current within two years and no instrument we read says which authority must issue it, and the 2018 form warns that a manufacturing licence is not the same thing as a GMP certificate. On the local side, Article 44(a) of Decree-Law 2/2025 requires the authorisation-holder to be seated in national territory, Article 44(d) requires a permanent and exclusive pharmacist as technical director, and Article 51 requires climate-controlled distribution.
The transition in the statute is the fact most easily glossed. Decree-Law 12/2004 was repealed in full by Article 77 of Decree-Law 2/2025 of 22 January 2025, and the DNFM's published forms still cite it as their legal basis. Article 56(2) of the new decree-law cross-refers to a separate decree-law on marketing authorisation; we searched the Jornal da República Série I for 2025 and 2026 and did not find it published. Diploma Ministerial 10/2004 sets the registration fee at USD 100 per medicine per form and dosage, though whether that schedule survives the repeal of its parent decree-law is unconfirmed. We searched in English, Portuguese and Tetum and found no body called ANMAS.
Quality Systems Behind Every Injectable Supplied to Timor-Leste
For a sterile injectable the technical file is where a Route B application is won, because no national laboratory stands behind it — the April 2025 policy records that there is currently no laboratory testing of medical products through national laboratories, while a physical sample still travels with the file. Expect aseptic process simulation records for the ISO Class 5 filling line, environmental monitoring trends, container-closure integrity, sterility and bacterial endotoxin testing by LAL, particulate matter, and validated HPLC and GC methods for assay and impurities.
On stability the instruments differ and both readings should be reported: the September 2023 checklist specifies three batches in Zone IVb, 30°C and 75% relative humidity, while the 2024 forms let the applicant declare Zone IVa, Zone IVb or other, and a published FAQ warns that a shorter shelf life may be applied where Zone IVb data cannot be provided. Shelf lives under 24 months are generally not acceptable, with exceptions. The bioequivalence rationale is scoped to oral solids and does not bite on injections. Neither Timor-Leste nor India appears on the PIC/S list of 54 participating authorities. Labelling must be in Tetum and Portuguese, or provisionally Indonesian or English.
Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry.
Why Farbe Firma is the Trusted Injectable Manufacturer in Timor-Leste for Global Buyers
Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries, positioning itself to serve Timor-Leste through a locally licensed importer. We build dossiers in CTD and ACTD format, which is the structure Route B asks for, and supply the WHO-format certificate of a pharmaceutical product, the manufacturing licence and the GMP certificate as a matter of course. Because the applicant must be based in Timor-Leste with an import licence and a pharmacist to sign, the route begins with a named local partner. Candidates are visible in the public record, but we have verified none and recommend none.
The bilateral relationship is young and its pharmaceutical content is thin but real. India announced a resident mission in Dili on 7 September 2023 and established the embassy on 5 September 2024. The two countries signed a memorandum on cooperation in healthcare on 7 April 2018, which expired in April 2023 and has been renewed for five years; it is a cooperation instrument, and we found nothing in it touching medicine registration, pharmacopoeial recognition or regulatory reliance. The Embassy of India in Dili reports total bilateral trade of USD 52.20 million in 2025–26; we could not locate a disaggregated pharmaceutical figure.
Where the money is, with every figure carrying its basis. Population is roughly 1.4 million: the World Bank estimate is 1,400,638 for 2024, while the 2022 census recorded 1,341,737 usual residents. Current health expenditure was 9.60% of GDP in 2023, up from 7.46% in 2022, but spending per person fell from USD 174.92 to USD 144.21 because GDP contracted — the share rose and the spending did not. Out-of-pocket payments were 6.99% of current health expenditure in 2023. Our own approximate count of INFPM's published medicine awards on 6 September 2026 is twelve lines totalling about USD 2.01 million, and a specialist-medicines tender with a USD 530,000 budget was open, closing 14 September 2026.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is India on Timor-Leste's list of recognised regulatory authorities?
No. Question E1 of the DNFM importer application form of January 2024 names ten agencies plus WHO prequalification, and India's CDSCO is absent, as it is from the 2018 form and the 2023 checklist. Absence is not exclusion: E1 selects Route A or Route B, and both end in a registration number. WHO's August 2026 list records CDSCO at maturity level 3 for vaccines only.
What law governs medicine registration in Timor-Leste?
The position is in transition. Decree-Law 12/2004 was repealed in full by Article 77 of Decree-Law 2/2025 of 22 January 2025, although the DNFM's published forms still cite it. Decree-Law 2/2025 regulates the licensing of import, storage, distribution, sale and export, and its Article 56(2) cross-refers to a separate decree-law on marketing authorisation that we searched for and did not find published. In practice the operative documents are the DNFM's form, checklist and DAIM procedure.
Does an Indian manufacturer need WHO prequalification to supply Timor-Leste?
No, but it changes the route. WHO prequalification is named on the form as a Route A qualifier, so a WHO-prequalified product takes the abridged route. Without it an Indian product goes to Route B. WHO prequalification is product- and site-specific; WHO-GMP certification by an Indian state licensing authority is a different thing, is not named on the form, and we found no instrument treating the two as equivalent.
Who buys injectables in Timor-Leste?
Mainly the state. SAMES was succeeded by the Instituto Nacional de Farmácia e Produtos Médicos under Decree-Law 57/2023, which procures, stores and distributes from a central warehouse in Dili and regional units at Ainaro, Baucau and Maliana. It publishes tenders and results with budgets, winning bidders and amounts; our own approximate count of its published medicine awards is twelve lines worth about USD 2.01 million. Suppliers must hold a valid import or wholesale licence to bid.
Does Farbe Firma have experience with ASEAN and Asia-Pacific markets?
Yes. Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries, including Asia-Pacific markets where the ASEAN Common Technical Dossier is the working format. We prepare dossiers in CTD and ACTD structure, generate Zone IV stability data, supply the WHO-format CPP and GMP certificate, and work through licensed local importers.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments